Open AccessPI3K Inhibitor Resistance & MAP Kinase Activation in CLL
Author(s) -
Richard Simoneaux
Publication year - 2021
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000753404.50810.fc
Subject(s) - idelalisib , chronic lymphocytic leukemia , bruton's tyrosine kinase , ibrutinib , medicine , rituximab , pi3k/akt/mtor pathway , tyrosine kinase , phosphoinositide 3 kinase , tyrosine kinase inhibitor , cancer , oncology , leukemia , cancer research , signal transduction , biology , lymphoma , receptor , biochemistry